5 Top Performing Stocks Of The Best ETF Of Q3
Zacks Investment Research | Sep 29, 2016 09:13PM ET
After a huge sell-off at the start of the year, the biotech sector has made a strong comeback with BioShares Biotechnology Clinical Trials Fund (MZ:BBC) topping the list of the best performing ETFs of 3Q16. The fund delivered impressive returns of about 29.6% in the quarter and has a Zacks ETF Rank of 3 or ‘Hold’ rating with a High risk outlook.
This is especially true given that a string of robust earnings results, hopes of increased M&A activity and accelerating pace of innovation brought confidence back into the sector. In addition, the stock market rally has compelled investors to hunt for beaten down growth stocks. However, increased regulatory scrutiny over high drug prices and political uncertainty surrounding healthcare reform in the wake of November elections continued to weigh on the sector performance (read: Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.